British pharmaceutical giant GlaxoSmithKline (GSK) has announced plans to pour $30 billion into the United States over the next five years, strengthening its research and manufacturing footprint in the world’s largest healthcare market.
The commitment was unveiled on Wednesday, coinciding with U.S. President Donald Trump’s state visit to the UK.
Trump, who has pressed global companies to ramp up production on American soil since his re-election, has imposed tariffs on industries he accuses of fueling the U.S. trade deficit.
“This week’s state visit brings together two countries that have led the world in science and healthcare innovation,” said GSK Chief Executive Emma Walmsley.
The investment package includes a $1.2 billion biologics plant in Pennsylvania aimed at advancing treatments for respiratory illnesses and cancer.
READ ALSO:UK Inflation Holds Steady in August, Dampening Hopes of Rate Cuts
GSK also plans to expand artificial intelligence programs across its five U.S. manufacturing facilities.
The company said the initiative will create “hundreds of highly skilled jobs” and boost its existing U.S. workforce of 15,000 employees.
The announcement underscores the growing importance of the American market for pharmaceutical firms as political and economic pressures mount on global supply chains.